Trials / Completed
CompletedNCT02483325
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Institut Paoli-Calmettes · Academic / Other
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible HLA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allogeneic transplant conditioning | Allogeneic transplant |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2018-03-01
- Completion
- 2020-03-01
- First posted
- 2015-06-26
- Last updated
- 2019-01-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02483325. Inclusion in this directory is not an endorsement.